159 related articles for article (PubMed ID: 12113036)
1. Clinical applications of radioprotectors.
Werner-Wasik M
Expert Rev Anticancer Ther; 2001 Aug; 1(2):309-16. PubMed ID: 12113036
[TBL] [Abstract][Full Text] [Related]
2. Amifostine--a radioprotector in locally advanced head and neck tumors.
Schönekäs KG; Wagner W; Prott FJ
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():27-9. PubMed ID: 10584137
[TBL] [Abstract][Full Text] [Related]
3. Amifostine: the first selective-target and broad-spectrum radioprotector.
Kouvaris JR; Kouloulias VE; Vlahos LJ
Oncologist; 2007 Jun; 12(6):738-47. PubMed ID: 17602063
[TBL] [Abstract][Full Text] [Related]
4. Amifostine and hematologic effects.
Sriswasdi C; Jootar S; Giles FJ
J Med Assoc Thai; 2000 Apr; 83(4):374-82. PubMed ID: 10808697
[TBL] [Abstract][Full Text] [Related]
5. [New data on cytoprotection in radiotherapy].
Sauer R; Strnad V
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():1. PubMed ID: 10584131
[No Abstract] [Full Text] [Related]
6. Radioprotective effects of amifostine.
Wasserman T
Semin Oncol; 1999 Apr; 26(2 Suppl 7):89-94. PubMed ID: 10348266
[TBL] [Abstract][Full Text] [Related]
7. [Cytoprotective effects of amifostine in the treatment of tumors].
Burkon P; Petýrek P; Spurný V
Vnitr Lek; 2003 Aug; 49(8):673-8. PubMed ID: 14518094
[TBL] [Abstract][Full Text] [Related]
8. Future development of amifostine as a radioprotectant.
Werner-Wasik M
Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
[TBL] [Abstract][Full Text] [Related]
10. Managing toxicities in pelvic malignancies.
Friedland J
J Support Oncol; 2004; 2(6 Suppl 3):19-23. PubMed ID: 15605921
[TBL] [Abstract][Full Text] [Related]
11. Tissue-protective effects of fullerenol C60(OH)24 and amifostine in irradiated rats.
Trajković S; Dobrić S; Jaćević V; Dragojević-Simić V; Milovanović Z; Dordević A
Colloids Surf B Biointerfaces; 2007 Jul; 58(1):39-43. PubMed ID: 17317115
[TBL] [Abstract][Full Text] [Related]
12. Studies on the radioprotective potency of amifostine on salivary glands of rats during fractionated irradiation: acute and late effects.
Sagowski C; Wenzel S; Metternich FU; Kehrl W
Eur Arch Otorhinolaryngol; 2003 Jan; 260(1):42-7. PubMed ID: 12520356
[TBL] [Abstract][Full Text] [Related]
13. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Bourhis J; Rosine D
Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
[TBL] [Abstract][Full Text] [Related]
14. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
15. Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers.
Anacak Y; Kamer S; Haydaroglu A
Pediatr Blood Cancer; 2007 May; 48(5):579-81. PubMed ID: 16395679
[TBL] [Abstract][Full Text] [Related]
16. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
[TBL] [Abstract][Full Text] [Related]
17. The use of amifostine to prevent xerostomia in patients receiving radiation therapy.
Batcha M
Oncol Nurs Forum; 2000 May; 27(4):615-6. PubMed ID: 10833684
[No Abstract] [Full Text] [Related]
18. [Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection].
Huang R; Yu H; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2002 Dec; 19(4):708-11. PubMed ID: 12561384
[TBL] [Abstract][Full Text] [Related]
19. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
Kouvaris J; Kouloulias V; Malas E; Antypas C; Kokakis J; Michopoulos S; Matsopoulos G; Vlahos L
Strahlenther Onkol; 2003 Mar; 179(3):167-74. PubMed ID: 12627259
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
